MX385229B - Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares. - Google Patents

Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares.

Info

Publication number
MX385229B
MX385229B MX2017017163A MX2017017163A MX385229B MX 385229 B MX385229 B MX 385229B MX 2017017163 A MX2017017163 A MX 2017017163A MX 2017017163 A MX2017017163 A MX 2017017163A MX 385229 B MX385229 B MX 385229B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
treatment
integrin antagonist
ocular conditions
alpha4 integrin
Prior art date
Application number
MX2017017163A
Other languages
English (en)
Other versions
MX2017017163A (es
Inventor
Achim Hans- Peter Krauss
Original Assignee
Axerovision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axerovision Inc filed Critical Axerovision Inc
Publication of MX2017017163A publication Critical patent/MX2017017163A/es
Publication of MX385229B publication Critical patent/MX385229B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se relaciona a antagonistas de integrina a4 y su uso en composiciones farmacéuticas, composiciones oftálmicas principalmente administradas tópicamente. Las composiciones farmacéuticas son útiles para tratar condiciones inflamatorias oculares, tales como enfermedad de ojo seco, uveítis no infecciosa (por ejemplo, anterior, intermedia, posterior, uveítis longitudinal), conjuntivitis no infecciosa, iritis o escleritis en animales, y particularmente mamíferos, incluyendo humanos.
MX2017017163A 2015-07-08 2016-07-07 Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares. MX385229B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Publications (2)

Publication Number Publication Date
MX2017017163A MX2017017163A (es) 2018-08-09
MX385229B true MX385229B (es) 2025-03-14

Family

ID=56373100

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017017163A MX385229B (es) 2015-07-08 2016-07-07 Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares.

Country Status (21)

Country Link
US (3) US10413535B2 (es)
EP (1) EP3319639B1 (es)
JP (2) JP6752276B2 (es)
KR (2) KR102440162B1 (es)
CN (1) CN107921136A (es)
AU (1) AU2016290197B2 (es)
BR (1) BR112018000112A2 (es)
CA (1) CA2989522C (es)
CL (1) CL2018000057A1 (es)
ES (1) ES2835274T3 (es)
HK (1) HK1247120A1 (es)
IL (2) IL256770B (es)
MA (2) MA42016A1 (es)
MX (1) MX385229B (es)
MY (1) MY187552A (es)
PL (1) PL3319639T3 (es)
RU (1) RU2018103940A (es)
TN (1) TN2017000538A1 (es)
UA (1) UA123728C2 (es)
WO (1) WO2017006272A1 (es)
ZA (1) ZA201708601B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200004789A (ko) * 2017-03-09 2020-01-14 알리스타 파마슈티컬즈, 인크. 안구 건조증 질환을 위한 펩티드
WO2018212846A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
CN114173802A (zh) * 2019-07-26 2022-03-11 急速制药有限责任公司 用于治疗非渗出性黄斑变性和其他眼睛病症的肽
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
CN101175488B (zh) 2005-05-17 2012-04-18 萨可德公司 治疗眼病的组合物和方法
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
UA123728C2 (uk) 2021-05-26
TN2017000538A1 (en) 2019-04-12
IL256770B (en) 2021-02-28
CA2989522A1 (en) 2017-01-12
BR112018000112A2 (pt) 2018-09-04
US20200000786A1 (en) 2020-01-02
MA44935A1 (fr) 2019-08-30
US20200405703A1 (en) 2020-12-31
JP2020121985A (ja) 2020-08-13
US20180200240A1 (en) 2018-07-19
EP3319639A1 (en) 2018-05-16
KR20180041122A (ko) 2018-04-23
MA42016A1 (fr) 2018-03-30
JP2018521126A (ja) 2018-08-02
AU2016290197B2 (en) 2021-07-22
CL2018000057A1 (es) 2018-06-22
RU2018103940A3 (es) 2019-09-03
JP6752276B2 (ja) 2020-09-09
EP3319639B1 (en) 2020-11-18
ES2835274T3 (es) 2021-06-22
US10413535B2 (en) 2019-09-17
MY187552A (en) 2021-09-29
ZA201708601B (en) 2019-05-29
WO2017006272A1 (en) 2017-01-12
CA2989522C (en) 2022-10-18
KR102440162B1 (ko) 2022-09-02
US10751334B2 (en) 2020-08-25
HK1247120A1 (zh) 2018-09-21
CN107921136A (zh) 2018-04-17
IL280827A (en) 2021-04-29
AU2016290197A1 (en) 2018-01-04
PL3319639T3 (pl) 2021-03-08
RU2018103940A (ru) 2019-08-08
MX2017017163A (es) 2018-08-09
IL256770A (en) 2018-03-29
KR20220062688A (ko) 2022-05-17

Similar Documents

Publication Publication Date Title
MX385229B (es) Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares.
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2018002924A1 (es) Inhibidores de bromodominios
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
SA518391624B1 (ar) Ror- منظمات جاما
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
MX375639B (es) Derivados de heterociclilos sustituidos como inhibidores de cdk
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
MX2019014122A (es) Formulaciones de dosis fija.
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
MX2017010348A (es) Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
EA201691160A1 (ru) Антагонисты s1p3
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
JOP20190054A1 (ar) مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
BR112017014379A2 (pt) composição para o tratamento de infecções causadas pelo acaro demodex spp
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
EP4017500A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANTERIOR BLEPHARITIS AND POSTERIOR BLEPHARITIS
UA120075C2 (uk) Фармацевтична композиція для лікування запальних змін прямої кишки